Peptide R (TFA)

• Description:

  Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research[1][2][3].

• UNSPSC:

  12352209

• Target:

  CXCR

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation

• Field of Research:

  Cancer

• Purity:

  98.34

• Smiles:

  O=C(N[C@@H](C)C(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CC=CC=C2)C(N[C@H]1CC3=CC=CC=C3)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N.OC(C(F)(F)F)=O.[x]

• Molecular Formula:

  C39H57N13O8S2.xC2HF3O2

• Molecular Weight:

  900.08 (free base)

• References & Citations:

  [1]Giulia Guidotti, et al. Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview. Cells. 2020 Feb 20;9 (2) :490. |[2]Vadim Le Joncour, et al. Seek & Destroy, use of targeting peptides for cancer detection and drug delivery. Bioorg Med Chem. 2018 Jun 1;26 (10) :2797-2806.|[3]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• Isoform:

  CXCR4